Suppr超能文献

针对发展中国家军事人群的病原体特异性疫苗成本效益分析的应用。

Application of a cost-effectiveness analysis of pathogen-specific vaccines against gastroenteritis to a military population in a developing country setting.

机构信息

Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St. Rm. W5519, Baltimore, MD 25101, United States; Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4799, United States.

Department of Internal Medicine, Naval Medical Center Portsmouth, 620 John Paul Jones Circle, Portsmouth, VA 23518, United States.

出版信息

Vaccine. 2020 Feb 28;38(10):2292-2297. doi: 10.1016/j.vaccine.2020.01.075. Epub 2020 Feb 1.

Abstract

Vaccine implementation planning in low- and middle-income countries (LMIC) often focuses on children without considering special adult populations. We adapted an economic model developed by the United States Department of Defense (DoD) to evaluate the cost-effectiveness of vaccine acquisition strategies for Campylobacter-, ETEC-, Shigella-, and norovirus-associated gastroenteritis. We compared implementation costs with current medical management in the Peruvian armed forces, a special population of low- and middle-income (LMIC) adults with a high incidence of infectious gastroenteritis. Pathogen-specific vaccine implementation resulted in calculated cost-effectiveness ratio (CER) per duty day lost averted (CER) of $13,741; $1,272; $301; and $803, and a CER per diarrhea day averted of $2,130; $215; $51; and $199 for Campylobacter, ETEC, Shigella, and norovirus, respectively. These estimates compare favorably to CER estimates from high-income military population and suggest that implementing vaccines gastroenteritis may be cost-effective in the Peruvian military population.

摘要

在中低收入国家(LMIC),疫苗实施计划通常侧重于儿童,而不考虑特殊的成年人群体。我们改编了美国国防部(DoD)开发的经济模型,以评估弯曲菌、肠产毒性大肠杆菌、志贺氏菌和诺如病毒相关肠胃炎疫苗获取策略的成本效益。我们将实施成本与秘鲁武装部队的现行医疗管理进行了比较,秘鲁武装部队是中低收入(LMIC)成年人中的一个特殊群体,他们患有传染性肠胃炎的发病率很高。针对特定病原体的疫苗实施导致每失去一个工作日的成本效益比(CER)分别为 13741 美元、1272 美元、301 美元和 803 美元,以及每避免一天腹泻的 CER 分别为 2130 美元、215 美元、51 美元和 199 美元,分别针对弯曲菌、肠产毒性大肠杆菌、志贺氏菌和诺如病毒。这些估计值与高收入军事人群的 CER 估计值相比具有优势,并表明在秘鲁军事人群中实施肠胃炎疫苗可能具有成本效益。

相似文献

2
Cost-effectiveness of norovirus vaccination in children in Peru.秘鲁儿童诺如病毒疫苗接种的成本效益
Vaccine. 2015 Jun 17;33(27):3084-91. doi: 10.1016/j.vaccine.2015.05.004. Epub 2015 May 15.
5
Global Economic Burden of Norovirus Gastroenteritis.诺如病毒肠胃炎的全球经济负担
PLoS One. 2016 Apr 26;11(4):e0151219. doi: 10.1371/journal.pone.0151219. eCollection 2016.

引用本文的文献

1
Vaccine value profile for norovirus.诺如病毒疫苗的价值概况。
Vaccine. 2023 Nov 3;41 Suppl 2(Suppl 2):S134-S152. doi: 10.1016/j.vaccine.2023.03.034. Epub 2023 Oct 6.

本文引用的文献

1
Tropical and travel-associated norovirus: current concepts.热带及与旅行相关的诺如病毒:当前概念
Curr Opin Infect Dis. 2015 Oct;28(5):408-16. doi: 10.1097/QCO.0000000000000197.
3
Cost-effectiveness of norovirus vaccination in children in Peru.秘鲁儿童诺如病毒疫苗接种的成本效益
Vaccine. 2015 Jun 17;33(27):3084-91. doi: 10.1016/j.vaccine.2015.05.004. Epub 2015 May 15.
5
Cost-effectiveness of rotavirus vaccination in peru.秘鲁轮状病毒疫苗接种的成本效益
J Infect Dis. 2009 Nov 1;200 Suppl 1:S114-24. doi: 10.1086/605043.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验